Wednesday, June 10, 2026
🇺🇸 FDA

pharma · Small Cell Lung Cancer · Metastatic castration-resistant prostate cancer (mCRPC)

Amgen

Amgen trial registry — 99 ClinicalTrials.gov studies with program phase, status, and indication context.

Website Investor relations
One Amgen Center Drive, Thousand Oaks, CA 91320, US HQ
1980 Founded
40,212 Employees
NMPA registrant Type
Company details
Status
Public
HQ
One Amgen Center Drive, Thousand Oaks, CA 91320, US
Founded
1980
Employees
40,212
Programs
96
Drugs
124
Patents
25
Official website ↗ All projects Drug pipeline Patents News & analysis

Recent coverage

View all news & analysis →
Intelligence · Clinical Trials

Amgen clinical trials

Registry index of 99 ClinicalTrials.gov studies linked to Amgen programs — each row shows trial ID, program name, phase, status, and indication.

Amgen trial registry — 99 ClinicalTrials.gov studies with program phase, status, and indication context.

Recent trial activity

8 updates

Latest clinical program signals indexed for Amgen.

  1. 20170724 — Phase 3

    Clinical update

  2. 20240031 — Phase 1

    Clinical update

  3. 20230298 — Phase 1

    Clinical update

  4. 20210184 — Phase 3

    Clinical update

  5. 20190135 — Phase 1

    Clinical update

  6. 20180146 — Phase 1

    Clinical update

  7. 20220028 — Phase 1

    Clinical update

  8. 20210098 — Phase 3

    Clinical update

Trial registry

99 studies
  4. 2023-503433-21-00

    20190531

    Phase 3 active small_molecule

    Behçet’s disease is a chronic, relapsing, multisystem inflammatory disorder of unknown etiology characterized by 4 major symptoms (oral aphthous ulcers, genital ulcers, skin lesions, and ocular lesions) and occasionally by 5 minor symptoms (arthritis, gastrointestinal ulcers, epididymitis, vascular lesions, and central nervous system [CNS] symptoms) (Cho, 2012). Juvenile idiopathic arthritis is a heterogeneous group of chronic inflammatory disorders that initially presents in children by the age of 16 years. It refers to arthritis of at least 6 weeks duration of unknown etiology that begins in children less than 16 years old. Juvenile idiopathic arthritis has an annual incidence of 2 to 20 cases per 100 000 population and a prevalence of 16 to 150 cases per 100 000 population. It is an autoimmune disorder marked by abnormalities of immune responses (Adelowo, 2010).

    CTIS ↗
  10. 2023-504364-42-00

    20220127

    Phase 2 active small_molecule

    In Part 1, subjects with advanced MTAP-null solid tumors and, in Part 2, subjects with advanced MTAP-null Non Small-Cell Lung Cancer

    CTIS ↗
  19. 2023-506136-32-00

    20180257

    Phase 2 active small_molecule

    Relapsed or Refractory B cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL) and Minimal Residual Disease Positive (MRD+) B-ALL,

    CTIS ↗
  24. 2023-507149-27-00

    20170770

    Phase 3 active small_molecule

    Chemotherapy-induced Thrombocytopenia in Adult subjects with Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer

    CTIS ↗
  26. 2023-508214-42-00

    20190009

    Phase 3 active small_molecule

    Previously treated locally advanced and unresectable or metastatic non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation

    CTIS ↗
  28. 2023-509047-26-00

    20220028

    Phase 1 active other

    Dose Escalation: Non-small cell lung cancer (NSCLC), colorectal cancer (CRC), gastric cancer (GC), melanoma (MEL). Dose Confirmation: Lead Indication based on data from dose escalation. Dose Expansion: Tertiary Lymphoid Structure positive (TLS+) CRC, GC, and NSCLC.

    CTIS ↗
  35. 2024-511195-33-00

    20230223

    Phase 1 active other

    Gastrointestinal tract, biliary tract, or pancreatic cancers with homozygous methylthioadenosine phosphorylase (MTAP)-deletion

    CTIS ↗
  55. 2024-520050-38-00

    20240178

    Phase 3 active small_molecule

    Extensive stage small cell lung cancer (ES-SCLC). Small-cell lung cancer, accounting for 10% to 15% of lung cancer (Rudin et al, 2015), is an aggressive lung cancer subtype with neuroendocrine differentiation and strongly associated with smoking (Koinis et al, 2016). It displays a distinct natural history characterized by a high growth fraction, rapid doubling time and early establishment of widespread metastatic lesions (Gustafsson et al, 2008). Around 70% of patients are diagnosed with ES-SCLC, presenting with distant metastasis or tumor or nodal volume that is too large to be encompassed in a tolerable radiation plan.

    CTIS ↗

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.